ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
AEON Biopharma Inc

AEON Biopharma Inc (AEON)

0.154
-0.0169
(-9.89%)
Closed January 17 4:00PM
0.1378
-0.0162
( -10.52% )
Pre Market: 8:18AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.1378
Bid
-
Ask
-
Volume
1,434,640
0.00 Day's Range 0.00
0.1013 52 Week Range 17.17
Market Cap
Previous Close
0.154
Open
-
Last Trade Time
08:18:42
Financial Volume
-
VWAP
-
Average Volume (3m)
16,745,976
Shares Outstanding
39,970,693
Dividend Yield
-
PE Ratio
0.25
Earnings Per Share (EPS)
0.6
Revenue
52.75M
Net Profit
24.05M

About AEON Biopharma Inc

AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-... AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
2022
AEON Biopharma Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AEON. The last closing price for AEON Biopharma was $0.15. Over the last year, AEON Biopharma shares have traded in a share price range of $ 0.1013 to $ 17.17.

AEON Biopharma currently has 39,970,693 shares outstanding. The market capitalization of AEON Biopharma is $6.16 million. AEON Biopharma has a price to earnings ratio (PE ratio) of 0.25.

AEON Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0022-1.571428571430.140.2230.10131796601950.16859056CS
4-0.4726-77.42463958060.61040.64330.1013570540350.17636448CS
12-0.8622-86.2211.020.1013167459760.18092738CS
26-2.2122-94.13617021282.352.99040.101374843550.20016221CS
52-7.7522-98.25348542467.8917.170.101341866420.46578435CS
156-10.0022-98.64102564110.1417.170.101328086000.50939685CS
260-10.0022-98.64102564110.1417.170.101328086000.50939685CS

AEON - Frequently Asked Questions (FAQ)

What is the current AEON Biopharma share price?
The current share price of AEON Biopharma is $ 0.1378
How many AEON Biopharma shares are in issue?
AEON Biopharma has 39,970,693 shares in issue
What is the market cap of AEON Biopharma?
The market capitalisation of AEON Biopharma is USD 6.16M
What is the 1 year trading range for AEON Biopharma share price?
AEON Biopharma has traded in the range of $ 0.1013 to $ 17.17 during the past year
What is the PE ratio of AEON Biopharma?
The price to earnings ratio of AEON Biopharma is 0.25
What is the cash to sales ratio of AEON Biopharma?
The cash to sales ratio of AEON Biopharma is 0.11
What is the reporting currency for AEON Biopharma?
AEON Biopharma reports financial results in USD
What is the latest annual turnover for AEON Biopharma?
The latest annual turnover of AEON Biopharma is USD 52.75M
What is the latest annual profit for AEON Biopharma?
The latest annual profit of AEON Biopharma is USD 24.05M
What is the registered address of AEON Biopharma?
The registered address for AEON Biopharma is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
Which industry sector does AEON Biopharma operate in?
AEON Biopharma operates in the BLANK CHECKS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CKXCKX Lands Inc
$ 18.00
(53.32%)
94
EONREON Resources Inc
$ 1.52
(49.02%)
42.04M
TPETTrio Petroleum Corp
$ 2.50
(40.45%)
11.45M
LMBODirexion Daily Crypto Industry Bull 2x Shares
$ 33.97
(26.32%)
319
BHMBluerock Homes Trust Inc
$ 14.38
(15.97%)
1
GLUGabelli Global Utility and Income Trust
$ 8.01
(-46.28%)
1
EIMEaton Vance Municipal Bond Fund
$ 6.01
(-40.96%)
1
SVTServotronics Inc
$ 7.01
(-33.75%)
3
GENCGencor Industries Inc
$ 13.20
(-20.34%)
14
ETUT Rex 2X Long Ether Daily Target ETF
$ 36.06
(-13.17%)
238
EONREON Resources Inc
$ 1.52
(49.02%)
42.04M
TPETTrio Petroleum Corp
$ 2.50
(40.45%)
11.45M
ETHU2x Ether ETF
$ 7.25
(-12.55%)
4.8M
MSTUT Rex 2X Long MSTR Daily Target ETF
$ 13.11
(-0.15%)
4.32M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 33.26
(2.37%)
2.86M

AEON Discussion

View Posts
tw0122 tw0122 5 days ago
All out at .19 good luck nice bottoming 
👍️0
glenn1919 glenn1919 5 days ago
AEON.......................................@.20 .........................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783







............thx.......................
👍️0
tw0122 tw0122 5 days ago
Bounce bounce break .14 see .20
At .13
👍️0
Backstabbed Backstabbed 1 week ago
$AEON - 2 filings released AH! SC-13G
👍️0
0210 0210 2 weeks ago
93m shs traded = 50m buys + 8m(?) vs. 35m sells: https://ih.advfn.com/stock-market/AMEX/aeon-biopharma-AEON/trades
👍️0
0210 0210 2 weeks ago
new lows still, hah! hmmm.....interesting AEON teens & twenties.
👍️0
0210 0210 2 weeks ago
aeon aeON AEON https://www.benzinga.com/news/25/01/42821213/why-aeon-biopharma-stock-is-down-65-today
👍️0
0210 0210 2 weeks ago
A/S 500m O/S 40m Float 10m. 70m traded so far today. buys > sells. hmmm....
👍️0
0210 0210 2 weeks ago
AEON 19-20cents way below all-time VWAPs and 50cents $20m new offering price!? hmmm....chap 11 pps? lolol.
👍️0
ErnieBilco ErnieBilco 2 weeks ago
Offering meltdown TIME TO BUY
👍️0
glenn1919 glenn1919 3 months ago
AEON............................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 months ago
AEON new 52=week low
👍️0
willlbone willlbone 6 months ago
Dilution.
👍️0
glenn1919 glenn1919 6 months ago
AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 6 months ago
AEON under $3
👍️0
glenn1919 glenn1919 6 months ago
AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
DewDiligence DewDiligence 6 months ago
AEON repositions ABP-450 as_a potential Botox biosimilar:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html

AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.

This looks like another instance of Zebra’s Law.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
Monksdream Monksdream 7 months ago
AEON new 52 week low
👍️0
Monksdream Monksdream 7 months ago
AEON new 52 week low
👍️0
DewDiligence DewDiligence 8 months ago
AEON—>55% workforce reduction—ABP-450 clinical development suspended:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs. AEON is all but insolvent—see #msg-174417740.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
DewDiligence DewDiligence 8 months ago
AEON has a liquidity problem—1Q24 results:

https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

No CC.
👍️0
DewDiligence DewDiligence 8 months ago
AEON plows on despite setbacks:

https://www.globenewswire.com/news-release/2024/05/09/2878729/0/en/AEON-Biopharma-Provides-Update-on-Development-Pipeline.html
👍️0
Monksdream Monksdream 9 months ago
AEON new 52+ week low
👍️0
DewDiligence DewDiligence 9 months ago
AEON—(-53%)—reports failed phase-2 in migraine prevention:

https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 10 months ago
Dilution from the redemption of warrants:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
👍️0
trglaa trglaa 10 months ago
What happened here today?
👍️0
DewDiligence DewDiligence 10 months ago
AEON 4Q23 financials:

https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
👍️0
DewDiligence DewDiligence 10 months ago
AEON updates plans for migraine program:

https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html
👍️0
DewDiligence DewDiligence 10 months ago
AEON sells $15M of convertible debt to_supplier, Daewoong:

https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
👍️0
DewDiligence DewDiligence 1 year ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

The above PR also includes preclinical data for ABP-450 in PTSD (!?).

AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON needs to raise cash very soon:

https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023. No quarterly CC.
👍️0
DewDiligence DewDiligence 1 year ago
AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance… Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
👍️0
trglaa trglaa 1 year ago
Nice run today.
👍️0
DewDiligence DewDiligence 1 year ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

See #msg-172274963 for related info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON's initial press release:

https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
👍️0
TESLA777 TESLA777 1 year ago
$AEON This is the one Im watching/trading tomorrow....GLTY......
👍️0
DewDiligence DewDiligence 2 years ago
AEON’s corporate slide presentation:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
👍️0
DewDiligence DewDiligence 2 years ago
AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
👍️0
DewDiligence DewDiligence 2 years ago
AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:

https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
👍️0